Explore a Decade of Genomic Innovation

Leading Life Science Innovation Contents Foreword�������������������������������������������������������������������3 Enhanced Genomic Discovery: The MGI Journey���������������������������������������������������������������������4 A New Era of Affordable Sequencing �������������������������13 The Visionaries Who Made Modern Genomics Possible ��������������������������������������������������� 14 10 Defining Milestones in MGI’s Genomics Journey ����������������������������������������������������15 Genomic Solutions Driving Innovation ������������������������ 22 Global Impact: MGI in Action ������������������������������������� 35 A Lifelong Journey of Genomic Discovery: Reflecting on a Decade of DNBSEQ Innovation and Beyond���������������������������������40 Resources����������������������������������������������������������������43 2Leading Life Science Innovation Foreword The story of genomics is one of humanity’s most ambitious scientific endeavors. What began as a decade-long, billiondollar international collaboration can now be accomplished a single day for less than $100. This transformation represents more than technological progress; it marks a fundamental shift in how we understand biology, diagnose disease, protect our environment, and feed our planet. Since its founding in 2016, MGI has consistently driven the field of genomics forward. As the only company to master all three key sequencing signal detection modes, delivering clinical-grade short and long read sequencers across the full throughput spectrum, MGI has established itself as a key player in the global genomics landscape. This eBook celebrates 10 years of innovation, growth, and global impact. It highlights the real-world applications of accessible genomic technology, from protecting Thailand’s coastal ecosystems to expanding precision medicine access across Latin America. It explores how the exponential growth in data generation is just the beginning of genomics’ next phase. Most importantly, it demonstrates how MGI is committed to making sequencing accessible worldwide, accelerating the pace of discovery, and collaborating to achieve the full potential that genomics offers. Listen to Their Stories Over the Past Decade Watch Video 3Leading Life Science Innovation Enhanced Genomic Discovery: The MGI Journey The story of genomics represents more than just technological progress; it marks a fundamental shift in how we understand biology, diagnose disease, protect our environment, and feed our planet. The volume of genetic data that can be generated has grown exponentially over the last decade, from kilobases using early pipette-based methods to terabases using modern platforms such as spatiotemporal chips. Genetic analysis that once cost billions of dollars and required over a decade of work can now be performed in hours for under $100. This democratization of sequencing technology has unlocked population-scale studies and opened new frontiers across precision medicine, agriculture, public health monitoring, and biodiversity conservation. Since its founding in 2016, MGI has been a catalyst in transforming the genomic landscape. As one of the few companies worldwide capable of independently developing and mass-producing clinical-grade gene sequencers across the full throughput spectrum, MGI has grown to serve over 3,560 users across more than 110 countries and regions. This eBook explores MGI’s journey of innovation and global expansion, highlighting the company’s strategic milestones that have defined the last decade. The evolution of genome sequencing The path to today’s sequencing revolution began with Frederick Sanger’s chain-termination sequencing method in the 1970s. This development enabled scientists to read DNA sequences and laid the foundation for the Human Genome Project, which became an international effort costing approximately $3 billion over the course of a decade. The next major shift came in the mid-2000s with the advent of next-generation sequencing (NGS), which leverages massively parallel sequencing (MPS) to analyze millions of DNA fragments simultaneously. This breakthrough reduced both costs and timeframes, enabling the transition from single-genome projects to population-scale studies and bringing genomics to thousands of laboratories worldwide. In the current market, modern sequencing techniques must balance a range of competing factors: throughput, accuracy, read length, cost per sample, and ease of use. Different applications demand different solutions, from ultra-high-throughput platforms capable of sequencing thousands of whole genomes for population studies, to compact benchtop systems suited for clinical laboratories performing targeted diagnostic panels. The field is accelerating as innovations in library preparation, automation, and data analysis make genomic information more accessible and actionable. Sequencing Challenges Accuracy Cost per sample Throughput Ease of use The different aspects of sequencing that need to be balanced. 4Leading Life Science Innovation MGI enters the field In 2016, we founded MGI with a clear mission: to develop and promote advanced life science tools for future healthcare. But our vision went deeper than simply developing new instruments. We saw an opportunity to democratize access to genomic technology worldwide. We envisioned creating an independent company capable of developing and manufacturing clinicalgrade sequencers across the full spectrum of applications. What drove this vision was not merely a commercial opportunity, but a conviction that genomic technology should be accessible to researchers, clinicians, and communities everywhere. From day one, MGI has innovated rapidly, responded to market needs, and expanded strategically and globally. It is an exciting time in the field of genomics, and the next decade holds as much promise for MGI as the last. — Duncan Yu, President, MGI Tech Co., Ltd. Product and technology innovation journey The technological foundation for MGI’s vision began with DNBSEQ™ (DNA Nanoball Sequencing). This proprietary sequencing approach creates compact “nanoballs” of DNA through rolling circle amplification, then sequences them on precisely patterned array chips using combinatorial probe-anchor synthesis (cPAS). This approach delivers distinct advantages: exceptional accuracy, low duplication rates, and minimal index hopping compared to other sequencing methods, characteristics that prove crucial for clinical applications. Since BGISEQ-500 was launched and achieved costs approaching $1,000 per genome, it has demonstrated that accessible, high-quality sequencing was possible. MGI’s journey toward commercialization began in 2016, when its product portfolio expanded with the benchtop G400 and G50 sequencers, serving laboratories with varying throughput needs and establishing MGI’s ability to manufacture clinical-grade instruments across multiple scales. BGISEQ-500 team building event. 5Leading Life Science Innovation The 1,000th G99 gene sequencer rolls off the production line. These early products laid the foundation for future innovations, establishing MGI’s credibility as a serious player in the global sequencing market. This was further enhanced in 2017 when MGI achieved ISO 13485 Medical Device Quality Management System certification, a crucial milestone demonstrating adherence to the highest international standards for medical devices. In October 2019, MGI launched three new product series: the DNBSEQ E series (including the world’s first selfluminescent sequencer), the DNBelab D series (microfluidic library preparation systems), and the DNBelab C series (single-cell analysis platforms). MGI’s portfolio also expanded beyond sequencing with the US-R3 robotic ultrasound system (first launched in 2017), which received both China’s NMPA and EU regulatory approvals and represented an entry into intelligent medical imaging. Product innovation continued at a rapid pace, and in September 2023, MGI launched the DCS (DNA Omics, Cell Omics, Spatial Omics) Lab Initiative. As of June 2025, 30 DCS labs were established globally, creating hubs for advanced research and collaboration. In February 2024, MGI introduced StandardMPS 2.0 sequencing reagents, which achieve Q40 sequencing quality—99.99% base-calling accuracy—a significant benchmark in the industry that sets new standards for clinical-grade sequencing. In September 2025, MGI formally organized its technology portfolio into three integrated business segments: SEQ ALL (a complete sequencing platform portfolio), GLI (Generative Lab Intelligence, encompassing automation and AI-driven laboratory solutions), and multi-omics (integrating single-cell analysis, spatial transcriptomics, and medical imaging). In 2026, MGI acquired STOmics and CycloneSEQ, delivering integrated long-read, short-read, and spatial omics solutions. This marks a significant milestone in MGI’s “SEQALL+GLI+Omics” strategy, positioning the company as the world’s only manufacturer of core life science tools spanning short-read sequencing, long-read nanopore sequencing, generative lab intelligence, and spatial omics technologies. 458+ International qualifications and certifications in total 85+ Product categories covered 90+ Countries and regions covered 23 11 DNBSEQ™ sequencers have NMPA approval for clinical use, accounting for nearly 60% of the total number of domestic certificates obtained. DNBSEQ™ sequencers support both DNA and RNA detection for comprehensive applications like pathogen detection and tumor RNA detection. 6Leading Life Science Innovation Data Privacy and Security MGI is committed to protecting your privacy. As a global enterprise, MGI takes all reasonable and legal solutions to meet the requirements of privacy protection to comply with local laws and regulations. Data Access MGI is a supplier of the technology and products for the customers. MGI does NOT provide any gene-sequencing services. MGI does NOT own, control, handle, or even access the genetic data, but MGI’s customers do. Security Safeguards MGI’s sequencers are designed to be able to run without connections to internet. Customers have 100% control of the data generated in the instrument. Without connecting to the internet, there is no risk from the internet of data access by people outside the lab. MGI’s sequencers are not equipped with any wireless data transmission module. The Wired NIC port is limited to build internal networks, such as a laboratory information management system (LIMS) connection. The USB port is used only for emergency data backup to prevent data loss if a customer’s intranet is under attack. Privacy Protection Policy MGI strictly abides by the principle of Privacy by Design. MGI’s product design and configuration are constructed through a comprehensive genetic data security and protection system. MGI also provides customers with specific suggestions on security and protection in terms of physical and technical environment for the equipment installation. Third Party Certificates MGI has acquired ISO 27001:2022 and ISO 13485:2016 certificates, with ISO 27701:2019 certification in process. ZTRON Appliance has been certified by European Privacy Seal (EuroPriSe) in privacy protection. Global expansion and customer experience journey MGI was officially founded in Shenzhen, establishing its headquarters and first production base. In the same year, it opened a production base in Wuhan, China. In 2017, MGI opened its production base in Changchun, China, launching the manufacturing infrastructure that would support global expansion. In 2019, a production facility was opened in Qingdao, China, to further expand manufacturing capacity to meet growing demand. The period from 2019 through 2021 marked MGI’s transformation from a promising startup to a global enterprise with manufacturing and customer support infrastructure spanning multiple continents. In November 2019, MGI opened an international production and logistics base in Riga, Latvia, providing a manufacturing presence outside China. 7Leading Life Science Innovation MGI achieves ISO13485 Medical Device Quality Management System certification and launches G400 and G50. MGI is officially founded. MGI launches ultra-high-throughput sequencer T7. 2016 2017 2018 2019 2021 2022 2023 MGI Latvia was established. MGI constructed an upgraded manufacturing hub in Wuhan. Reagent production line launched in Qingdao. MGI moved into new headquarters in Shenzhen. 8Leading Life Science Innovation 2021 2022 2023 2024 2025 Australia Hong Kong Singapore UK and Japan Germany and Brazil MGI has spent half a decade opening Customer Experience Centers, which provide researchers and clinicians with hands-on technical support� In 2020, the COVID-19 pandemic tested healthcare systems and diagnostic capabilities worldwide, demonstrating the critical importance of accessible, reliable sequencing technology for global health security. As demand for the technology grew, it became necessary to provide customers with hands-on access to technology, training, and local support. This drove the development of Customer Experience Centers (CEC), facilities where researchers and clinicians could experience training and ongoing technical support. The first international CEC opened in Australia in 2021, followed by centers in the United Kingdom and Japan (both 2022), Hong Kong (2023), Germany and Brazil (both 2024), and Singapore (2025). Each CEC became a hub for local scientific communities, hosting workshops, supporting collaborative research, and ensuring that MGI’s technology integrated smoothly into diverse laboratory workflows. 9Leading Life Science Innovation Recent innovations and market leadership The years 2022 through 2025 marked MGI’s maturation as a global enterprise and continued technological leadership. In September 2022, MGI went public on the Shanghai Stock Exchange STAR Market (stock code: 688114.). The same year brought another significant milestone when, in July 2022, it was awarded $334 million in settlement of intellectual property litigation. In 2022, MGI also constructed an upgraded manufacturing hub in Wuhan for products related to the life science and biotechnology sectors, meeting world-class standards. In 2024, MGI unveiled European headquarters in Berlin, Germany, further strengthening its infrastructure for serving customers across continents. On September 9th, 2022, MGI went public on the Shanghai Stock Exchange with the stock code 688114. By September 2025, MGI’s global workforce had grown to over 2,200 people, with approximately 27% dedicated to research and development. More than 5,300 DNBSEQ and CycloneSEQ sequencing platforms have been sold worldwide, and MGI’s service network continues to expand. *Statistics as of 30 September, 2025 **Statistics as of 13 April, 2026 2,241 employees worldwide, of which 27.04%* are Research and Development employees 1,132 valid patent applications (cumulative) 3,560+ users in 100 countries/ regions worldwide 5,300+ DNBSEQ and CycloneSEQ sequencing platforms sold and installed globally 18,000+ papers published in top scientific journals** 10Leading Life Science Innovation HQ in Shenzhen Global impact and scientific contributions At the close of December 2025, there were over 18,000 scientific articles published using DNBSEQ and CycloneSEQ platforms. These publications span the biological spectrum, from population genomics and cancer research to environmental monitoring and archaeology. The applications extend far beyond human health. In agriculture, MGI technology supports crop breeding programs worldwide, enabling researchers to develop more resilient, productive varieties suited to changing climate conditions. This global impact hasn’t gone unrecognized, and MGI has received numerous prestigious awards, including a Green World Award for sustainable contribution in 2025, a special mention in TIME Magazine’s Best Inventions of 2024, a Gold Edison Award in 2024, and an R&D 100 Award in 2023. MGI has also worked hard to establish strategic partnerships with leading research institutions, clinical laboratories, and agricultural organizations worldwide. From Thailand’s National Omics Centre to the University of Lisbon, MGI’s technology is enabling researchers and clinicians to address their communities’ most pressing challenges. The global reach of MGI San Jose, US Boston, US North America London, UK Stockholm, Sweden Riga, Latvia Berlin, Germany Belgrade, Serbia Europe Dubai, UAE Middle East Brisbane, Australia Oceania Changchun Beijing Kunshan Chengdu Qingdao Shanghai Wuhan Hong Kong Singapore Tokyo, Japan Asia São Paulo, Brazil South America Regional Office Comprehensive Base (Production/R&D/Marketing) Customer Experience Center (CEC) 11Leading Life Science Innovation A decade of progress, decades of possibility ahead MGI’s first decade has been marked by rapid evolution. Throughout this journey, MGI has remained committed to making genomic technology accessible worldwide while maintaining the highest standards of quality and performance. The following sections of this eBook provide detailed explorations of MGI’s key technologies, product lines, and application areas. You’ll glimpse the future taking shape in MGI’s laboratories and partner institutions worldwide, and you’ll see how MGI is building a future where intelligent systems accelerate discovery, where comprehensive multi-omics analysis reveals biology’s full complexity, and where the tools of life science serve researchers and communities everywhere. Discover how MGI’s innovations are transforming life science research and clinical applications aking reat nnovations Discover A Decade of Making Great Innovations. Learn More 12A NEW ERA OF AFFORDABLE SEQUENCING In just over two decades, genome sequencing has transformed from a billion‑dollar scientific moonshot into an accessible tool driving discovery worldwide. Unlock the power of low-cost sequencing References 1� Gunukula SR� Whole Genome Sequencing Cost 2023� 3billion� Published 29 December, 2022� Accessed 13 February, 2026� https://3billion�io/blog/whole-genomesequencing-cost-2023 2� Schwarze K, Buchanan J, Fermont JM, et al� The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom� Genetics in Medicine. 2020;22(1):85–94. doi: 10�1038/s41436-019-0618-7 2003 $3 billion1 • After 13 years of hard work, the Human Genome Project completes the human genome sequence • Next-generation sequencing emerges • Costs begin rapid decline • The “$1,000 genome” barrier broken • Population-scale studies become feasible • MGI launches T7 • High-throughput platforms accelerate cost reduction • Ultra-highthroughput systems enable sub-$100 genomes and produce up to 50,000 WGS per year (T20×2) • T7+ and T20×2 drive accessibility 2007 $1 million1 2014 $1,0001 2018 $6002 2025 <$100 Volume of Data Cost Terabases KilobasesTHE VISIONARIES WHO MADE MODERN GENOMICS POSSIBLE Every breakthrough in science stands on the foundation laid by those who came before. The genomics revolution that MGI advances today was made possible by decades of pioneering. Mid-2000s: The NGS Revolution Early genomic research teams including those of Radoje Drmanac, Jonathan Rothberg, and David Klenerman Next-generation sequencing technologies enabled massively parallel sequencing, analyzing millions of DNA fragments simultaneously. Costs plummeted from millions to thousands of dollars. Sequencing time dropped from years to days. This opened the door for genomics to move from research labs into clinical medicine and population studies. Discover the legacy of genomics with the latest tools from MGI 1953: The Double Helix James Watson, Francis Crick, and Rosalind Franklin The discovery of DNA’s double helix structure revealed how genetic information is stored and replicated. For the first time, scientists could visualize the molecule of heredity—establishing the foundation for all subsequent molecular biology research. Understanding DNA’s structure made it possible to imagine reading its sequence. 1990–2003: The Human Genome Project International Consortium of Researchers The first complete human genome sequence involved mapping 3 billion base pairs over 13 years at a cost of $3 billion. This proved that genome sequencing was possible and created the reference that all future genomics would build upon. It also demonstrated the need for faster, more affordable sequencing technologies to make genomics accessible. 2005–Present: Complete Genomics and DNBSEQ™ Radoje Drmanac and the MGI Team DNA Nanoball Sequencing (DNBSEQ™) technology achieves unprecedented accuracy through combinatorial probe-anchor synthesis on patterned arrays. High accuracy, low duplication rates, and minimal index hopping enable clinical-grade sequencing at scale. Costs continue to fall toward the sub-$100 genome. Genomics is becoming democratized, making precision medicine, population health studies, and agricultural genomics accessible across continents. From the double helix to DNA nanoballs, each generation of scientists has pushed the boundaries of what’s possible—building tools that allow the next generation to see further. Today, MGI carries this legacy forward, developing technologies that bring the power of genomics to researchers, clinicians, and communities worldwide. 1977: Reading the Code Frederick Sanger The chain-termination sequencing method enabled the first practical way to read DNA sequences. Sanger sequencing made it possible to determine the exact order of DNA bases, earning Sanger his second Nobel Prize. This method powered the Human Genome Project and remained the gold standard for decades.Leading Life Science Innovation 10 Defining Milestones in MGI’s Genomics Journey Over the last decade, MGI’s journey has fundamentally shaped how genomic research is conducted and how healthcare is delivered. By breaking down the barriers of high-throughput sequencing, MGI has turned cutting-edge technology into an accessible reality for laboratories worldwide. Its journey has been defined by a series of transformative milestones— from proprietary sequencing platforms to landmark studies—that have driven significant progress across the global scientific community. To mark this decade of progress, this listicle highlights 10 ways MGI has made lasting impacts on genomics research and healthcare. 1� Driving high-speed results at a fraction of the price In 2017, MGI fundamentally changed the cost–performance ratio in next-generation sequencing with the launch of the G400 and G50. These sequencers offer affordable, high-quality sequencing, with both systems capable of completing a PE100 run in under 48 hours. By supporting four or more distinct read lengths, they offer researchers flexibility across a broad range of applications—from clinical diagnostics and forensics to agriculture and environmental engineering. Launch of the G400 production line in Latvia. 15Leading Life Science Innovation The G50 generates up to 60 gigabases (Gb) per run from a single flow cell and the G400 produces up to 600 Gb per run across two flow cells. This 10-fold difference in throughput opens the door to rapid and reliable genomic insights for laboratories at all scales. 2� Unleashing ultra-high-throughput power High costs and slow turnarounds have long constrained large-scale sequencing, until the launch of the T7 in 2018 shattered these constraints. Built for unprecedented speed and throughput, the T7 produces up to 7 Tb of data per day, transcending the daily production capacity of all other platforms at the time. Its 24-hour turnaround for PE150 runs has proven vital for rapid-response clinical needs, spearheading critical viral characterization and vaccine development efforts. As demands grew for quick data handling on a large scale, 2025 saw the arrival of the T7+, an upgraded powerhouse that packs accuracy and flexibility into a smaller footprint. This instrument leverages four independent flow cells to deliver over 14 Tb of ultra-high-quality sequencing data in 24 hours. Moreover, it integrates an intelligent 7-in-1 workflow from DNB preparation to analysis, allowing researchers to process 35,000 whole human genomes annually. Today, these scalable sequencers remain the gold standard for high-speed, data-intensive research and clinical applications. 3� Pioneering self-luminous sequencing The launch of the E25 in 2022 changed the face of portable sequencing. As the world’s first sequencer to leverage selfluminous technology, the E25 eliminates the need for complex external excitation sources. Its compact and lightweight design achieves unrivalled portability for on-the-go analyses, making sequencing accessible far beyond the confines of traditional labs into airports, customs, and remote field locations. Powered by a microfluidics-based flow cell with integrated complementary metal-oxide-semiconductor (CMOS) modules, the E25 delivers FASTQ data from a DNA sample in just 20 hours. Its microfluidic chips remove the need for washing between runs, further enhancing its ability to operate in settings without traditional infrastructure. The T7+ launch. 16Leading Life Science Innovation 4� Setting a new pace In 2022, MGI launched its ninth sequencer model, the G99, one of the fastest mid- to low-throughput sequencers on the market. It utilizes a first-of-its-kind triangular matrix flow cell to achieve higher data density, delivering 8–48 Gb per run and completing PE150 runs in just 12 hours. Crucially, MGI’s pursuit of speed doesn’t come at the cost of quality: the G99 maintains a remarkably low error rate, averaging 0.2%. These capabilities make the G99 ideal for targeted and small genome sequencing, particularly for precision oncology and rapid tumor detection in hospitals. Its real-world utility was proven during the discovery of the first imported case of Monkeypox in Chongqing, China. 5� Breaking the sub-$100 genome barrier For decades, the cost of whole genome sequencing (WGS) remained a significant hurdle for large-scale research. Even as prices dropped from millions in the mid-2000s to around $600 by early 2023, the field was still far from achieving true population-scale affordability. The launch of T20×2 in 2023 redefined the economics of large-scale sequencing, becoming the first platform to break the sub-$100 genome barrier. This record-breaking sequencer produces up to 50,000 whole genomes per year, with a massive 72 Tb output per PE150 run, making it uniquely suited for large-population genome projects. The low cost and high throughput of the T20×2 are possible thanks to its unique ability to handle six open-type large sequencing slides simultaneously. Its innovative dip-immersion biochemistry and robotic handling ensure uniform reactions across these large slides. The G99 at the University of Lisbon, sequencing the Sahara dust storm. The T20×2. 17Leading Life Science Innovation 6� Delivering full-spectrum sequencing In 2024, the CycloneSEQ product line, including G100-ER and G400-ER, was introduced, equipped with nanopore technology for real-time long-read sequencing. Powered by an innovative flow cell design and advanced base-calling algorithms, the CycloneSEQ sequencers bridge the gap between long-read accuracy and high-throughput performance. The G100-ER provides essential flexibility across diverse sample types and workflows in small- to mid-scale projects. Meanwhile, the G400-ER stands as the world’s highest-throughput single-chip nanopore sequencer. Designed for high-output applications such as whole-genome resequencing and single-cell full-length transcriptome studies, it enhances both cycle time and efficiency. 7� Transforming benchtop sequencing Historically, mid-throughput sequencing has been a bottleneck, plagued by slow turnarounds and inflexible workflows. The launch of the T1+ in 2025 broke this cycle by delivering 1.2 Tb of data with full PE150 workflow completion in just 24 hours—all while maintaining Q40 quality metrics exceeding 90%. Designed for flexibility, the T1+ supports three flow cell formats and leverages independent flow cell lanes to handle multiple projects simultaneously. Its optimized internal design also minimizes reagent consumption, maximizing cost-efficiency. This combination of speed, economy, and versatility makes the T1+ the definitive solution for accelerated discoveries in tumor sequencing, WGS, whole exome sequencing (WES), and multi-omics studies. The T1+ launch. 18Leading Life Science Innovation 8� Conquering the extremes In 2024, MGI proved that genomic innovation knows no geographic bounds by successfully deploying the E25 and G99 platforms at an altitude of 5,200 meters on Mount Everest. Despite extremely low-temperature, low-oxygen conditions, both sequencers delivered stable, high-quality data. The portable E25 excelled in on-field sample testing, showcasing its portability and low environmental requirements. The G99 demonstrated benchtop sequencing comparable to controlled lab environments across six rounds of testing. As well as the highest peaks, MGI’s research contributions extend to the deepest oceans. Utilizing DNBSEQ technology, researchers generated high-resolution genome and metagenome data from samples in the Mariana Trench.1,2,3 These insights advanced understanding of adaptations to extreme environments and provided evidence for ecological protection and sustainable resource utilization. 9� Reaching global impact Over the past decade, MGI has transitioned from an emerging technology developer into a global infrastructure, as evidenced by its pivotal role in 69 population-based studies worldwide. Key examples include the South Africa 110K Human Genome Program, which brought high-throughput sequencing to Africa at a previously impossible scale, and the Brazil National Genomics Program (Genomas Brasil), which is sequencing 100,000 genomes to advance rare disease research. MGI also supports The Genomics Thailand Initiative to boost the nation’s research competitiveness and medical standards. By March 2025, this programme successfully completed Phase One, including WGS of 50,000 individuals. These efforts are closing the global data gap to improve regional disease prevention and treatment. MGI’s commitment to global impact extends to the Million Microbiomes of Humans Project (MMHP), a 10-country collaboration to map the microbial diversity of 1 million individuals. The launch of the 110K Human Genome Program in South Africa. The E25 on Mount Everest. 19Leading Life Science Innovation Beyond population genomics, MGI has established leadership in specialized academic research, with its single-cell platform contributing to over 120 SCI-indexed publications. Further cementing its research leadership, MGI launched the DCS Lab Initiative in 2023, establishing 30 labs worldwide and providing end-to-end workflows for advanced research in DNA genomics, cell omics, and spatial omics. At the heart of MGI’s new era is the “SEQALL+GLI+Omics” vision. In February 2026, MGI Tech officially solidified this strategy by announcing the acquisition of STOmics and CycloneSEQ. This move transformed MGI into a comprehensive one-stop solution provider, offering a suite of short-read sequencing, long-read nanopore sequencing, generative lab intelligence, and spatial omics technologies. Unifying these capabilities under one roof empowers MGI to meet the increasingly diverse needs of global customers across multiple technology platforms. 10� Advancing beyond automation into lab intelligence In 2025, MGI launched the Generative Lab Intelligence (GLI) department, a strategic upgrade of its legacy laboratory automation business spearheading the life sciences industry’s paradigm shift from manual experience-led operations to AI-driven, data-centric decision making. Built on a full-stack product portfolio spanning AI intelligent solutions, universal automation hardware, computing and storage infrastructure, and end-to-end smart lab solutions, GLI enables seamless scalability from benchtop research labs to industrial-scale production facilities, with a proprietary wet-dry closed-loop system powered by multi-agent collaborative technology. GLI Product Family From “centimeter-scale” laboratory to “factory-scale” production laboratory, it covers all scenarios� Lab on Chip Lab on Desk Lab on Cube Lab as Factory Automated Liquid Handling Platform Intelligent Digital Platform Customized Platform Automated Devices and Consumables Integrated Platform Automatic Sampling Device Consumables CDMO Integrated Solution STP-3000 D4 SP-100 SP-960 SP-Smart 8 AlphaTool PrepALL αLab Studio αCube STP-7000 SP-NE32 MegaBOLT/ZBOLT STP-B1000 SP-NEX SP-NE384 FLP-L50 FLP-L Portable Smart Sampler-Water AIO Glab 50K Sample Pretreatment Sample Preparation Nucleic acid extraction Universal Pipetting 20Leading Life Science Innovation By 2026, nearly a decade of evolution in liquid handling systems culminated in the launch of PrepALL, a highperformance, compact system that makes “smart pipetting” accessible to all. Parallel to this, MGI’s library preparation has evolved into the All-in-One (AIO) Library Preparation and Sequencing System, which utilizes modular technology and AI to create a seamless, closed-loop, “sample in, report out” workflow. This marks MGI’s evolution from applicationspecific instruments to a full-stack GLI portfolio spanning AI intelligent solutions, universal automation hardware, computing and storage infrastructure, and end-to-end smart lab turnkey solutions, anchored by the breakthrough new generation of liquid handling innovation with PrepALL. The αCube Data Center Appliance, the core computing engine of the GLI ecosystem, integrates BT, IT, and AI to automate complex bioinformatics via the αBP platform, accelerating WGS workflows and supporting large-scale genomic studies. Complementing this is αLab Studio, the central intelligent brain of the framework, an AI-powered management platform that enables full-process intelligent orchestration from experimental design to autonomous execution, bridging the gap between automation and smart collaboration for end-to-end laboratory management. Validated by mega-scale national genomic projects and global commercial deployments, this integrated GLI system empowers breakthroughs across multi-omics research, biopharmaceutical R&D, clinical diagnostics, and public health—redefining industry standards for autonomous, scalable and future-ready smart laboratories. Conclusion MGI’s journey over the last decade has been defined by an evolution from a sequencing hardware manufacturer into a pioneer of integrated life sciences, now delivering a true‘ SEQALL+GLI+Omics’ one-stop solution. From supporting national population cohorts to enabling research in the world’s most extreme environments, these milestones showcase an ecosystem built for impact. As a global leader in integrated short-read, long-read, and spatial omics solutions, MGI remains a vital partner in the effort to turn complex biological data into life-saving medicine. Follow MGI’s journey here References 1. Xiao X, Zhao W, Song Z, et al. Microbial ecosystems and ecological driving forces in the deepest ocean sediments. Cell. 2025;188(5):1363–1377. doi: 1016/j. cell.2024.12.036 2. Zhang H, Sun S, Liu J, et al. The amphipod genome reveals population dynamics and adaptations to hadal environment. Cell. 2025;188(5):1378–1392. doi: 10.1016/j. cell.2025.01.030 3. Xu H, Fang C, Xu W, et al. Evolution and genetic adaptation of fishes to the deep sea. Cell. 2025;188(5):1393–1408. doi: 10.1016/j.cell.2025.01.002 21Leading Life Science Innovation Genomic Solutions Driving Innovation The technology that powered MGI’s record-breaking achievements is at the heart of the portfolio presented here. This section outlines how MGI’s proven technologies and solutions deliver the reliability and precision necessary to solve your most complex sequencing challenges. Key sequencing approaches As the only company globally to master all three key sequencing signal detection modes—excited-luminous, self-luminous, and non-luminous—MGI provides a level of versatility unmatched in the industry. Excited-luminous High-precision lasers hit DNA nanoballs (DNBs) on patterned array flow cells, exciting fluorescent tags attached to DNA bases, which then emit light. A P C G C A T G T A T A C Self-luminous A portable solution where a biochemical reaction within the DNB generates light when a base is incorporated, allowing an embedded complementary metal-oxide-semiconductor (CMOS) sensor to capture the signal directly. A P A T C A C G T G T A C A G C T C Non-luminous A solution for long-read sequences and real-time data. DNA passing through nanopores generates unique electrical signatures for each nucleotide, enabling accurate sequence identification. 22Leading Life Science Innovation SEQ ALL sequencing platform MGI distinguishes itself as the only global manufacturer capable of mass-producing both short-read and longread instruments, which have been unified into the SEQ ALL platform. E25 • Self-luminous sequencing • Ultra-portable • Handles tasks from sequencing to report generation • Daily data throughput of up to 7.5 Gb T20×2 • Excited-luminous sequencing • Ultra-high throughput • Processes up to 6 slides per run • Enables sub-$100 whole human genome sequencing G99 • One of the fastest speeds amongst medium- to low-throughput sequencers • Optional built-in bioinformatics module for streamlined analysis • Dual flow cell configuration for flexible throughput T1+ • Rapid benchtop sequencer • Dual flow cell for concurrent operation • Three flow cell options for flexibility • One-click DNB preparation and loading DNA Nanoball Sequencing (DNBSEQ™) technology Short-read sequencing at every scale, combining unmatched accuracy, speed, and efficiency. 23Leading Life Science Innovation T7+ • Ultra-high throughput • Annual capacity of 35,000 whole human genomes • 7-in-1 intelligent workflow • Over 90% of generated data achieves a Q40 quality score CycloneSEQ nanopore sequencing technology Leverages non-luminous sequencing and an innovative base-calling algorithm model for accurate, real-time base calling. Sequencing consumables Library prep kits and sequencing reagents for precise library preparation and high-quality sequencing. G100-ER • Portable • Rapid • Two independent flow cells for simultaneous operation • Enables throughput of up to 85 Gb G400-ER • Features a highthroughput, high-density flow cell, combining long read lengths, high data output, and real-time sequencing. • Detects base modifications • Suitable for complex genomes Learn more about SEQ ALL Sequencer products 24Leading Life Science Innovation Generative Lab Intelligence (GLI) AI-driven automation of liquid handling platforms streamlines sample pretreatment, nucleic acid extraction, sample preparation, and pipetting. Liquid handling system All in one PrepALL • Excellent pipetting performance • Cost effective • Simplified setup and deployment • Intelligent user experience • Open-source hardware/software design AIO • Fully automated workflow from sample to answer • Flexible sample throughput with independent pipetting • Built-in self-luminous sequencer for fast turnaround time PrepALL-pP8G • Built upon PrepALL to fully integrate single-cell sorting and proteomics workflows • Ultra-high throughput parallel sorting • Full-range precision dispensing • AI-powered intelligent single-cell recognition • Gentle thermal inkjet technology ensuring high cell viability • Versatile applications across multiple proteomics methods 25Leading Life Science Innovation SIRO-48 • Parallel sample processing allows fully unattended library preparation • Integrated, closed-system workflows for data consistency • Compact integration enables fast deployment across clinical or research settings and reduces operating costs Software and bioinformatics αCube Data Center Appliance • High-performance heterogeneous computing architecture provides extreme computing power • Large capacity and high-density storage • AI-powered bioinformatics analysis • Elastic scalability and easy expansion for flexibility αLab studio • Intelligent scheduling system (Nexus) leverages AI to orchestrate tasks, equipment, and personnel for stable, high-throughput workflows • Laboratory information management system (LIMS) provides end-to-end digital lifecycle management, enabling standardization, traceability, and quality control • Sample management system (SMS) delivers full-chain sample tracking from intake to transfer, ensuring data integrity, consistency, and regulatory compliance • Electronic laboratory notebook (ELN) captures and archives data for excellent reproducibility and auditability • Digital twin (DT) system builds a real-time virtual lab for simulation, monitoring, predictive analysis, and system-level optimization © 2025 MGI All rights reserved. 5IF
ē-BC˳
4UVEJP
-BCPSBUPSZ
*OUFMMJHFOU
.BOBHFNFOU
1MBUGPSN
EFFQMZ
JOUFHSBUFT
MBSHF
"*
NPEFMT
XJUI
BVUPNBUJPO
UFDIOPMPHJFT
5ISPVHI
JOUFMMJHFOU
EFDJTJPO

NBLJOH
EZOBNJD
TDIFEVMJOH
BOE
EBUB
NBOBHFNFOU
JU
BDIJFWFT
EJHJUBM
VONBOOFE
BOE
TUBOEBSEJ[FE
NBOBHFNFOU
PG
UIF
FOUJSF
FYQFSJNFOUBM
QSPDFTT Learn more about GLI products 26Leading Life Science Innovation Multi-Omics In 2025, MGI elevated its Novel Business segment into a dedicated Multi-Omics business unit—a strategic move at the heart of its “Full-Life Digitization” vision. This unified ecosystem brings together DNA genomics, cell omics, spatial omics, proteomics, mass spectrometry, automated biobanking, and ultrasound imaging, empowering researchers with a holistic toolkit that captures biological complexity across dimensions. PopOmics Integrated high-throughput sequencing solutions with end-to-end automation for population-scale genomic, methylation, transcriptomic, and metagenomic studies. Cell Omics Supports sample encapsulation and library prep for single-cell research. Combined with MGI’s other technologies, it covers end-to-end workflows from storage and transport to data analysis. TaiM 4 • Part of MGI’s one-stop DNBelab C Series platform • Compact, portable droplet generator for 1–4 single-cell samples per run • Supports scRNA-seq and scATAC-seq with fast, high-throughput encapsulation using dual-bead microfluidics YellowR 16 • Stable power through precise negative pressure-driven oil-in-water droplet generation • Supports flexible loading of 1–4 samples • Supports diverse library preparation methods 27Leading Life Science Innovation DNBelab C series high-throughput single cell RNA library preparation set v3.0 • Sensitive detection of genes • 1–4 samples per run to choose from flexibly • Efficient and stable cells recovered • Fast droplet generation • Accurately identifies multiple cell beads STOmics An array of products for mapping gene and protein expression at single-cell resolution. Stereo-seq Transcriptomics Solution v1.3 • High Sensitivity: Superior capture efficiency delivering significantly higher gene counts per cell • Flexibility: Supports multiple chip sizes (up to 13 cm x 13 cm) and broad species/tissue compatibility • Unbiased Discovery: Limitless whole-transcriptome profiling even for low-quality (low RIN) samples Stereo-seq OMNI Transcriptomics for FFPE Solution v1.1 • Enhanced FFPE Performance: 1× to 3× higher sensitivity for deeper biological insights from clinical samples • True Single-Cell Resolution: Superior diffusion control ensures precise cell-level annotation and stratification • Optimized Data Yield: Over 100% increase in usable data for more efficient clinical research Stereo-CITE Proteo-Transcriptomics Solution v1.1 • Multi-omics Integration: Simultaneously captures spatial RNA and 100+ protein markers in a single tissue section • Advanced Synergy: Combines the power of Stereo-seq and CITE-seq technologies 28Leading Life Science Innovation Go Spatial • Highly Automated: Achieves automation of post-imaging biochemical reactions built around Stereo-seq slide cassettes, reducing manual intervention steps and batch-to-batch variability • Consistent and Reliable Performance: Precision pipetting and temperature control deliver highly reproducible, standardized results • User-Friendly: An intuitive graphical interface that simplifies user training and streamlines experimental workflow G400RS FluoXpert • Enables seamless switching between automated high-throughput sequencing and fluorescence staining and imaging • AI-powered multiplex immunofluorescence (mIF) image analysis solution PMIF-20 • Fully automated staining and imaging system • Leverages mIF technology to capture precise spatial protein expression data in tissue sections Proteomics Learn more about multi-omics products 29Leading Life Science Innovation Gas chromatography–mass spectrometry In addition to the DNA, cell, spatial, and proteomics (DCSP) suite, the integration of mass spectrometry introduces small molecule detection—such as metabolomics and lipidomics—to the multi-omics ecosystem for the first time. 7700B GC-MS • Utilizes an inert ceramic electron ionization (EI) source • Equipped with a pre-quadrupole • Instrument detection limit (IDL) of <10 fg for ultra-trace analytes • Exceptional signal-to-noise (S/N) ratio • Features a discontinuous discrete electron multiplier • Streamlines workflows with auto-shutdown, flow protection, and batch data processing • Qualification Safety Standard (CE): Compliant with EN 61010- 1:2010+A1:2019 • Testing and Certification: DEKRA Test Report No. 2250100R.51A, Result: Pass • ISO Certifications: • ISO 9001 (QMS): Certificate No. 123725Q10183R0M • ISO 14001 (EMS): Certificate No. 123725E10151R0M • ISO 45001 (OH&S): Certificate No. 123725510152R0M • Validity: Production license valid until June 3, 2029; ISO certificates valid until September 3, 2028 30Leading Life Science Innovation Sample storage Automated biobanking solutions engineered for the safe, long-term storage of valuable biological samples. Featuring fully automated sample access, high storage capacity, and intelligent management, delivering precise, efficient, and reliable services for modern biobanks and research centers. Automated low-temperature biobanking CLab-RG Series • Low-temperature automated sample storage system • Temperature range: 4 °C/-20 °C • Fully automated and efficient access capabilities • Customizable solutions to address large-scale sample storage requirements CLab-LT Series • Ultra-low temperature automated sample storage system • Enables large-scale sample preservation at -80 °C • Fully automated and efficient access capabilities • Customizable solutions to address large-scale sample storage requirements CLab-FZ Series • Enables large-scale sample preservation at -80 °C • Triple cooling system: -80 °C, -20 °C, with LN2 backup • Supports automated access to single tubes and whole boxes • 90K/150K tubes storage capacity options • Automatic defrosting with air cooling • Emergency sample retrieval through maintenance door 31Leading Life Science Innovation Automated cryogenic sample storage Auxiliary product CLab-LN55K Pro • Provides a vapor phase liquid nitrogen storage environment: The top of the tank is < −180 °C, and the tube-picking area is ≤ −150 °C • Supports automated access to single tubes and whole boxes • Compatible with SBS standard format cryogenic tubes • Storage capacity: 0.5 mL ≥ 55K tubes; 2 mL ≥ 24K tubes CLab Capper • A benchtop instrument custom-designed for SBS-format cryotubes • Adapts to end-to-end automated workflows • A single capping/uncapping operation takes ≤ 20 seconds 32Leading Life Science Innovation Ultrasound platform Built around a smart healthcare ecosystem of intelligence, remote connectivity, and automation, MGI delivers accessible, intelligent ultrasound services to remote areas, emergency scenes, and community settings worldwide. R3 • The world’s first remote ultrasound robot requiring no onsite specialist, enabling real-time expert diagnosis via 5G • From ICU and emergency to ambulances and remote field sites • Supports in-hospital, pre-hospital, community, and off-site scenarios • Quick deployment for frontline, rural, and international rescue missions • Enables seamless collaboration across departments and locations EF6-CL • C-Convex (2–5 MHz) and L-Linear (4–13 MHz); one-touch switching • For superficial tissues (thyroid, vessels, muscles) and deep tissues (abdomen, obstetrics) • One-click expert consultation with real-time, AI-assisted diagnosis • Voice control, wireless fast charging, IPX7 waterproof, lightweight, and multiple modes 33Leading Life Science Innovation Applications Onco-genomics The DNBSEQ platform has served as the global platform of choice for oncology, supporting third-party adaptations for cancer diagnostics in Portugal, breast cancer diagnostics in Japan, and proactive genetic screening for breast cancer in Italy. Environment and biodiversity MGI has enabled landmark ecological studies that are changing the face of biodiversity research, advancing our understanding of how environments shape microbial communities in extreme environments and driving mangrove conservation efforts in Thailand. Public health MGI provides rapid-response solutions for the genomic surveillance of emerging viruses, such as Nipah, chikungunya, and monkeypox, while supporting long-term research into “elite controllers” of HIV in South Africa. Agriculture and food safety In Australian horticulture, a major genomics initiative utilizes MGI’s highthroughput sequencing and automation platforms to optimize crop yield, quality, and climate resistance. Archaeology The ancient genome of the Chinese Emperor Wu of Northern Zhou was sequenced using the G99, providing insights into his appearance, disease susceptibility, and ancestry. Molecular breeding Molecular breeding is becoming more accessible through MGI’s low-pass whole-genome sequencing, which is being utilized in Latin America to enhance the breeding and genetic improvement of crops. MGI’s sequencing technologies are more than just advanced hardware; they are the engines driving global breakthroughs. Explore the details of research successes in the case studies below. 34Leading Life Science Innovation Global Impact: MGI in Action Whether navigating Thailand’s wild mangroves, Portugal’s extensive vineyards, or the controlled precision of Colombia’s clinical labs, MGI’s sequencing technology is empowering researchers and healthcare providers worldwide to address critical challenges in environmental conservation, agricultural sustainability, and precision medicine. These three stories showcase how accessible, high-quality genomic tools are driving discovery and innovation across continents. Protecting Thailand’s Coastal Ecosystems For centuries, mangroves have served as Thailand’s coastal guardians—natural barriers protecting communities from coastal erosion and storm surges while providing critical habitat for marine species. Yet over the past 50 years, more than 60% of Thailand’s mangrove forests have disappeared, leaving coastal communities increasingly vulnerable. Dr. Jeremy Shearman, Senior Researcher at Thailand’s National Omics Centre (NOC), explained the urgency: “Mangroves are essential for coastal regions and estuaries. They offer erosion protection from surf and storm damage, and they provide nurseries for young marine life that replenish ocean stocks.” Dr. Jeremy Shearman Senior Researcher Thailand’s National Omics Centre Dr. Wirulda Pootakham Director Thailand’s National Omics Centre 35Leading Life Science Innovation Achieving effective conservation of these regions requires a deep understanding of the ecosystem at a genetic level. To assess mangrove genetic diversity, the team set out to build comprehensive reference genomes and shed light on genetic variation across different mangrove populations—all while maintaining cost-effectiveness for large-scale environmental monitoring. NOC partnered with MGI to deploy the G400RS sequencer, utilizing two complementary approaches: restriction-site associated DNA sequencing (RAD-seq) for population structure analysis, and RNA sequencing to reveal adaptive mechanisms in high-salt environments. Genomic analysis revealed distinct genetic subpopulations of mangroves, separated by natural mountain barriers, with flower size emerging as a key factor influencing population subdivision. Alarmingly, the data indicate that popular mangrove species are losing their genetic diversity because replanting relies on seeds from a limited, uniform gene pool. “Building a reference genome database for 15 mangrove species allows us to assess genetic diversity more accurately,” explained Dr. Wirulda Pootakham, Director of NOC. “This is vital for prioritizing conservation efforts.” The genetic maps that were generated now enable science-based restoration strategies that preserve local genetic resilience, directly supporting Thailand’s HM King Rama IX International Botanical Garden for Mangroves—the world’s first botanical garden collecting all global mangrove species. Watch the full story 36Leading Life Science Innovation Turning Dust Into Data: Agricultural Innovation in Portugal In southern Portugal, an unexpected environmental phenomenon is transforming agricultural research. Saharan dust events are now twelve times more frequent due to climate change, transporting millions of microorganisms across the Mediterranean, profoundly altering soil and plant microbiomes in Portuguese vineyards. With support from MGI’s G99 platform, researchers at the University of Lisbon have been mapping the microbial composition of dust, soils, and plants to understand how these bioaerosols affect grape quality, disease resistance, and crop yields. The high-sensitivity sequencing enables real-time analysis of millions of microorganisms, allowing early risk detection and identification of biotechnological opportunities. “The impact of dust is bidirectional,” explained Prof. Ricardo Dias, researcher at the University of Lisbon. “It can bring risks that threaten productivity, but it also carries microorganisms with biotechnological potential. We need to monitor and understand both sides.” During Storm Célia, which in 2022 deposited Saharan dust across regions of Spain, the team identified a bacterial genus with the potential to act as a natural fertilizer. They’ve also been testing non-native microbial consortia that increase vineyard resilience, improve grape quality, and reduce pesticide dependency. “Our partnership with the University of Lisbon demonstrates how sequencing can turn dust into data— starting in vineyards but ultimately building a system of microbial intelligence for agriculture at large,” stated Duncan Yu, President of MGI. Professor Ricardo Dias Researcher University of Lisbon Watch the full story 37Leading Life Science Innovation In Brazil, access to advanced genomic diagnostics has historically been limited by high costs and infrastructure challenges. Yet the nation’s healthcare landscape is undergoing a dramatic transformation through a strategic alliance between MGI and Dasa, the largest medical diagnostics company in Latin America. In 2024, Dasa partnered with MGI to implement a comprehensive genomic sequencing workflow across its laboratory network. The installation includes MGI’s high-throughput T7 sequencer, automated sample preparation systems SP-100 and SP-960, and the ZTRON data platform. This approach creates an integrated solution that significantly increases laboratory efficiency while reducing processing time and overall costs. “Our expertise in specialized health services combined with MGI’s sequencing technologies will ensure greater access for Brazilian patients to precision genomics,” explained Gustavo Riedel, Director of Genomics LATAM at Dasa. “This will help in defining more accurate and effective treatments for illnesses such as cancers and rare diseases.” Transforming Healthcare Access in Brazil: MGI and Dasa Advance Precision Medicine Gustavo Riedel Director of Genomics LATAM Dasa 38Leading Life Science Innovation Learn more about collaborating with MGI The impact extends beyond technical capabilities. By making genomic testing more accessible and affordable, the partnership is democratizing precision medicine in Brazil. Patients who previously would have faced prohibitive costs or long wait times can now access the genetic insights needed for personalized treatment decisions. “With the new platform, we have gained a lot in quality, timeliness, productivity, standardization of routine processes and data processing,” Riedel noted. “We want to guarantee more access for the population, in the shortest possible time, at an increasingly affordable cost.” Carlos Carpio, MGI’s General Manager for Latin America, emphasized the broader vision: “We are excited to leverage MGI’s technology and Dasa’s expertise in the diagnostics sector and extensive healthcare network. We will help enhance Dasa’s ability to serve an increasing number of patients by processing high-quality genetic samples that are more accessible and efficient.” The partnership represents more than technology implementation; it highlights a commitment to strengthening genomics infrastructure throughout Latin America’s largest nation, advancing personalized medicine, and ensuring that cutting-edge healthcare reaches the populations that need it most. Watch the full story 39Leading Life Science Innovation A Lifelong Journey of Genomic Discovery: Reflecting on a Decade of DNBSEQ Innovation and Beyond Commentary by Dr� Radoje Drmanac, CSO of MGI / Co-Founder of Complete Genomics August 2025 This year marks a decade since DNBSEQ technology, painstakingly created and developed by my team and me, was commercialized. As a father and a grandfather myself, DNBSEQ is my other baby—or not so much a baby now. At 10 years old, I imagine it as on the cusp of adolescence, running around with friends and thinking and sounding almost like a “grown-up”. The last 10 years went by in a blink, and as I reflect on my journey in genomics (which spans far beyond these 10 years), I am filled with pride and awe at how far we as an industry have come. Making my mark When I started college in Serbia studying molecular biology in 1977, the Sanger and Maxam–Gilbert sequencing methods were invented. Then, in 1986, the world welcomed the first commercial DNA sequencer, the ABI Prism 370A, touting a throughput of 1,000 bp per day. A year later, I invented sequencing by hybridization and soon after DNA microarrays as the first massively parallel sequencing (MPS) solution for efficient genome sequencing. In 1991 I moved with my team from Serbia to Argonne National Laboratories as part of the Human Genome Project (HGP), which became a pivotal moment that set the stage for the revolutionary advancements we see today. The project was not just about mapping the human genome; it was about unlocking the secrets of life itself. I proposed and developed DNA sequencing-by-hybridization, which laid the groundwork for more efficient and higherthroughput sequencing methods. Arriving at a turning point The HGP marked the beginning of a new era in biology, akin to sending humans to the moon. It showed us that largescale projects were feasible and sparked a demand for sequencing more genomes. The project made shorter reads more usable by providing a reference genome, enabling exome and panel sequencing. It was personally also a “light bulb moment”, inspiring me to start Complete Genomics, with the goal of maximizing the potential of MPS. 40Leading Life Science Innovation In 2005, amidst the arrival of next-generation sequencing, my team and I invented patterned arrays of DNA nanoballs (DNB), which significantly expanded MPS’ capabilities and became the DNBSEQ sequencing platform. This technology offers unparalleled accuracy, eliminating clonal errors and index hopping while generating higher signal density. It was the key to Complete Genomics achieving the milestone of sequencing a human genome for $5,000 in 2010, demonstrating that routine, affordable, and accurate whole-genome sequencing was not only possible but also beneficial. Our merger with MGI allowed us to further develop DNBSEQ and introduce the BGISEQ-500, the first commercial sequencer based on DNBSEQ, in 2015. Witnessing the fruits of our endeavors I recall the watershed moment when we decided to expand beyond just providing whole human genome sequencing services and develop our own commercial sequencer. At the time, we did not have a dedicated engineering or technology development arm. I advised starting an engineering team in MGI, and this led to the hiring of senior engineer Yongwei Zhang, who spoke both English and Chinese to help bridge the gap between the two sites. Yongwei, who has remained at MGI, was instrumental in building the BGISEQ-500. I vividly recall the wave of emotions that swept over me as I saw the machine for the first time, and I was even more astonished to see not just one—but 50 and even 100 of them —in production. Over the past decade, we have continually pushed the envelope in what DNBSEQ can do to global critical acclaim. To date, users from 100 countries and regions across six continents have published more than 10,000 high-level articles using the DNBSEQ platform, involving more than 5,406 species studied and fully verifying its advantages in data quality and many other aspects. DNBSEQ now serves as the backbone of MGI’s suite of cutting-edge sequencing instruments, including the versatile G400 benchtop sequencer, and the ultra-fast T7 with a throughput of 1–7 Tb per day. More recently, we also launched the T1+, one of the fastest T-level benchtop sequencers globally with the capability of completing a sequencing workflow in only 24 hours. Indeed, genomics has advanced at an incredible pace, with sequencing costs falling dramatically. From the $3 billion spent on the first human genome to sub-$100 genomes made available today by way of our T20×2 ultra-high throughput sequencer, this journey has surpassed Moore’s Law predictions. I have long envisioned a future where molecular health monitoring becomes an integral part of everyday life. These recent developments in DNBSEQ are making routine genome sequencing for all a more tangible reality than ever. My team and I are determined to reach a $10 genome through advancements like increased DNB array density, our single-tube long fragment read (stLFR) technology, CycloneSEQ technology, and other novel technologies, enabling affordable fully phased, highly accurate, and complete whole-genome sequencing for health monitoring, personalized medicine, and other applications. Welcoming a future of unlimited possibilities The journey from when nucleic acids were first isolated in 1869, to the HGP, and the current era of genomics has been a testament to human ingenuity and collaboration. The applications of sequencing technologies are vast and ever expanding. I look forward to celebrating 10 years of the G400 or 10 years of the T7, and I’m excited about what these platforms will bring to genomics and life science in the coming years. In this past decade since DNBSEQ was commercialized, it has not only transformed the field of genomics but also empowered numerous national genome projects around the world and paved the way for improved global health. As DNBSEQ continues to evolve, we prepare to leverage its potential and ring in a new era where genomics will touch every aspect of our lives, promising a future where health and longevity are within our grasp. This year, we are not just celebrating a milestone; we are embracing the limitless possibilities of DNBSEQ that lie ahead. 41Discover the power of the T7+ The End of Compromise T7+ Ultra-high throughput meets unparalleled efficiency The T7+ delivers over 14 terabases of high-quality data within 24 hours, providing an annual capacity of up to 35,000 whole-genome sequences. 7-in-1 intelligent integration From DNB preparation to sequencing, the T7+ provides a fully automated, streamlined workflow that reduces manual intervention and accelerates time-to-results. Designed for accuracy at scale Whether you’re conducting population genomics, cancer research, or multi-omics studies, the T7+ handles your most demanding projects with clinical-grade accuracy.Leading Life Science Innovation Resources Explore MGI’s cutting-edge technologies and real-world applications through a wide range of videos. From product demonstrations to expert interviews, discover how MGI is advancing genomics and empowering scientific discovery across precision medicine, research, and beyond. Video Library Dive into the fascinating world of genomic science with an expert-led webinar series. Learn from top scientists as they explore the latest applications and innovations transforming genomics research and clinical practice. Webinar Join MGI for engaging conversations about the genomics revolution. Whether you’re a seasoned researcher or new to the field, this podcast features in-depth discussions and interviews with leading experts who are shaping the future of genomic science. Podcast As a global genomics company, MGI is committed to developing innovative technologies that improve lives around the world. The latest ESG Report outlines MGI’s latest progress, challenges, and priorities as they work toward a more sustainable future. ESG Report 43